Earnings & Results
Hindustan Bio Sciences Swings to ₹31.04 Lakh Profit as Other Income Drives Q2
By News Desk ·
Key takeaways
- Hindustan Bio Sciences reported a net profit of ₹31.04 lakh in Q2FY27, reversing a loss of ₹5.85 lakh a year earlier.
- Other income of ₹85.04 lakh drove total income to ₹82.21 lakh, while revenue from operations was ₹2.83 lakh.
- The board accepted Company Secretary Shailendra Vyas's resignation effective October 31, 2026.
Hindustan Bio Sciences reported a net profit of ₹31.04 lakh for the second quarter of fiscal year 2027, reversing a loss of ₹5.85 lakh in the same period last year, ScanX reported on October 31, 2026. The Hyderabad-based pharmaceutical company makes finished dosage forms including injectables, tablets, capsules, syrups, drops, ointments and pre-filled syringes, along with a licensed nephrology drug, Recombinant Human Erythropoietin.
How Hindustan Bio Sciences Reached the Profit
The board approved the unaudited standalone results at a meeting on October 31, 2026. Total income for the quarter was ₹82.21 lakh, against ₹0.86 lakh a year earlier. Revenue from operations was ₹2.83 lakh, while other income contributed ₹85.04 lakh.
Total expenses rose to ₹54.00 lakh from ₹6.71 lakh. Cost of material consumed was ₹46.13 lakh and employee benefit expenses were ₹5.72 lakh. Basic earnings per share came to ₹0.30, compared with negative ₹0.06 in the year-ago quarter.
For the half-year ended September 30, 2026, the company posted a profit of ₹19.74 lakh, against a loss of ₹4.45 lakh in H1FY26. The board also accepted the resignation of Shailendra Vyas as Company Secretary and Compliance Officer, effective from the closing hours of October 31, 2026. Vyas cited an alternative career opportunity outside the organization, and his resignation letter was enclosed as Annexure B to the regulatory filing.
Hindustan Bio Sciences' Recent Quarter in Company Records
According to akta.pro company records, Hindustan Bio Sciences reported zero sales and a net loss of Rs 0.11 crore in Q1 FY27, the quarter ended June 2026, against a net profit of Rs 0.01 crore in the same quarter a year earlier. Revenue in that quarter compared with Rs 0.32 crore in Q1 FY25.
In Q3 FY26, the quarter ended December 2025, the company reported sales of Rs 0.38 crore and a net profit of Rs 0.08 crore at an 18.42% operating margin, a reversal from a net loss of Rs 0.04 crore in the same quarter a year earlier.
Board Meeting and Capital Reduction Before the Results
On August 26, 2026, ScanX reported that Hindustan Bio Sciences would hold a board meeting on August 31, 2026, at its Hyderabad registered office to consider a revised notice for the 34th AGM and a draft scheme for share capital reorganization.
On July 31, 2026, ScanX reported a Q1FY27 net loss of ₹11.29 lakh, compared with a profit of ₹1.40 lakh in Q1FY25, with revenue dropping to zero. Expenses remained flat at ₹11.29 lakh, driven primarily by employee costs.
What Follows the October 31 Board Meeting
The resignation of Shailendra Vyas as Company Secretary and Compliance Officer took effect from the closing hours of October 31, 2026, the date of the board meeting that approved the Q2FY27 results.